A jury has said that Johnson & Johnson must pay $8 billion in the case over male breast growth linked to Risperdal.
List view / Grid view
Filter the results
Drugmakers that face litigation over the opioid crisis are looking at ways to settle the cases by using Purdue's bankruptcy, it has been reported.
Following positive clinical trials, the Tagrisso drug has been given marketing authorisation in China for treatment of NSCLC.
The Philippines is considering re-introducing a dengue vaccine whose use was ceased because of links to several deaths.
Whether by ignorance of the latest best practices, or willful disregard for patient safety, the results of careless practice can often be fatal. The articles in this in-depth focus highlight how regulatory bodies are taking action to raise the industry’s game.
The CMA has revealed findings that provisionally show that four pharmaceutical companies have broken the law.
Member countries of WHO have agreed to support pricing transparency for medicines, vaccines and other health products.
Teva has agreed to pay Oklahoma, resolving allegations that illegal marketing of its medication contributed to the state’s opioid epidemic.
FDA sends warning to Petra Hygienic Systems Int LTD after they find violations of current good manufacturing practices (cGMPs).
A coalition of 43 attorneys general allege generic drug manufacturers colluded, overcharging US states and consumers billions.
Amgen and Astellas Pharma US have agreed to pay a total of $124.75 million to settle allegations that they paid kickbacks to Medicare copays for their own medications.
In a ruling handed down by the UK Supreme Court, Lord Hodge has confirmed that discoveries made through well-established or routine research protocols can be inventive and rewarded with a patent.
With the UK bracing itself for a 'no-deal' Brexit or some other outcome that has not yet been determined, pharma experts discussed the potential effect of Brexit on the supply chain and how to best prepare for it against the upcoming deadline.